KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2025)

Royalty Pharma's Other Accumulated Expenses history spans 6 years, with the latest figure at $53.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 22.5% year-over-year to $53.2 million; the TTM value through Dec 2025 reached $53.2 million, down 22.5%, while the annual FY2025 figure was $53.2 million, 22.5% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $53.2 million at Royalty Pharma, up from $3.1 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $97.5 million in Q2 2024 and bottomed at $3.1 million in Q2 2025.
  • The 5-year median for Other Accumulated Expenses is $12.4 million (2022), against an average of $28.4 million.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 503.08% in 2024 before it tumbled 96.85% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $4.3 million in 2021, then surged by 187.44% to $12.4 million in 2022, then decreased by 8.27% to $11.4 million in 2023, then surged by 503.08% to $68.6 million in 2024, then dropped by 22.5% to $53.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other Accumulated Expenses are $53.2 million (Q4 2025), $3.1 million (Q3 2025), and $3.1 million (Q2 2025).